Karine Miquel‐Hébert

发表

Temporal changes of coronary artery plaque located behind the struts of the everolimus eluting bioresorbable vascular scaffold

R. Whitbourn, P. Serruys, S. Garg, 2011, The International Journal of Cardiovascular Imaging.

A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods

Patrick W Serruys, Yoshinobu Onuma, Evelyn Regar, 2009, The Lancet.

Four-year clinical follow-up of the ABSORB everolimus-eluting bioresorbable vascular scaffold in patients with de novo coronary artery disease: the ABSORB trial.

Patrick W Serruys, Yoshinobu Onuma, John A Ormiston, 2012, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

Vascular response of the segments adjacent to the proximal and distal edges of the ABSORB everolimus-eluting bioresorbable vascular scaffold: 6-month and 1-year follow-up assessment: a virtual histology intravascular ultrasound study from the first-in-man ABSORB cohort B trial.

R. Whitbourn, P. Serruys, H. Garcia-Garcia, 2012, JACC. Cardiovascular interventions.

Monitoring in vivo absorption of a drug-eluting bioabsorbable stent with intravascular ultrasound-derived parameters a feasibility study.

Patrick W Serruys, Yoshinobu Onuma, Evelyn Regar, 2010, JACC. Cardiovascular interventions.

Evaluation of the Second Generation of a Bioresorbable Everolimus Drug-Eluting Vascular Scaffold for Treatment of De Novo Coronary Artery Stenosis Six-Month Clinical and Imaging Outcomes

R. Whitbourn, P. Serruys, S. Windecker, 2010 .

Serial in vivo intravascular ultrasound-based echogenicity changes of everolimus-eluting bioresorbable vascular scaffold during the first 12 months after implantation insights from the ABSORB B trial.

R. Whitbourn, P. Serruys, S. Windecker, 2011, JACC. Cardiovascular interventions.

Clinical and intravascular imaging outcomes at 1 and 2 years after implantation of absorb everolimus eluting bioresorbable vascular scaffolds in small vessels. Late lumen enlargement: does bioresorption matter with small vessel size? Insight from the ABSORB cohort B trial

R. Whitbourn, P. Serruys, S. Windecker, 2012, Heart.

ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease c

P. Serruys, H. Garcia-Garcia, B. Chevalier, 2012, American heart journal.

Evaluation of the Second Generation of a Bioresorbable Everolimus Drug-Eluting Vascular Scaffold for Treatment of De Novo Coronary Artery StenosisClinical Perspective

R. Whitbourn, P. Serruys, S. Windecker, 2010 .

Evaluation of the Second Generation of a Bioresorbable Everolimus Drug-Eluting Vascular Scaffold for Treatment of De Novo Coronary Artery Stenosis: Six-Month Clinical and Imaging Outcomes

R. Whitbourn, P. Serruys, S. Windecker, 2010 .

Two-year clinical, angiographic, and intravascular ultrasound follow-up of the XIENCE V everolimus-eluting stent in the treatment of patients with de novo native coronary artery lesions: the SPIRIT II trial.

P. Serruys, M. Beijk, J. Tijssen, 2009, Circulation. Cardiovascular interventions.

Five‐year long‐term clinical follow‐up of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: The SPIRIT FIRST trial

P. Serruys, F. Neumann, J. Piek, 2010, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

Five-year long-term clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery disease: the SPIRIT II trial.

P. Serruys, Y. Onuma, Karine Miquel-Hébert, 2013, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

Four‐year clinical follow‐up of the XIENCE V everolimus‐eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: The SPIRIT II trial

P. Serruys, S. Garg, Karine Miquel-Hébert, 2011, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

Differentiated analysis of an everolimus-eluting stent and a paclitaxel-eluting stent among higher risk subgroups for restenosis: results from the SPIRIT II trial.

P. Serruys, C. Macaya, J. Berland, 2008, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

Circumferential evaluation of the neointima by optical coherence tomography after ABSORB bioresorbable vascular scaffold implantation: can the scaffold cap the plaque?

Bernard Chevalier, Patrick W Serruys, Richard Rapoza, 2012, Atherosclerosis.

An everolimus‐eluting stent versus a paclitaxel‐eluting stent in small vessel coronary artery disease: A pooled analysis from the SPIRIT II and SPIRIT III trials

Patrick W Serruys, Gregg W Stone, P. Serruys, 2010, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

Systemic exposure of everolimus after stent implantation: a pharmacokinetic study.

P. Serruys, J. Piek, C. Macaya, 2008, American heart journal.

Efficacy of everolimus eluting stent implantation in patients with calcified coronary culprit lesions: Two‐year angiographic and three‐year clinical results from the SPIRIT II study

P. Serruys, J. Piek, A. Seth, 2010, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

Incidence and Potential Mechanism(s) of Post-Procedural Rise of Cardiac Biomarker in Patients With Coronary Artery Narrowing After Implantation of an Everolimus-Eluting Bioresorbable Vascular Scaffold or Everolimus-Eluting Metallic Stent.

P. Serruys, A. Baumbach, H. Garcia-Garcia, 2015, JACC. Cardiovascular interventions.

A pooled gender based analysis comparing the XIENCE V(R) everolimus-eluting stent and the TAXUS paclitaxel-eluting stent in male and female patients with coronary artery disease, results of the SPIRIT II and SPIRIT III studies: two-year analysis.

P. Serruys, G. Stone, A. Lansky, 2010, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

P. Serruys, H. Garcia-Garcia, B. Chevalier, 2012, American heart journal.

Evaluation of the Second Generation of a Bioresorbable Everolimus Drug-Eluting Vascular Scaffold for Treatment of De Novo Coronary Artery Stenosis: Six-Month Clinical and Imaging Outcomes

Bernard Chevalier, Patrick W Serruys, Yoshinobu Onuma, 2010, Circulation.

Two-Year Clinical, Angiographic, and Intravascular Ultrasound Follow-Up of the XIENCE V Everolimus-Eluting Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions: The SPIRIT II Trial

P. Serruys, M. Beijk, J. Tijssen, 2009 .